España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Keros Therapeutics
KROS
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
Get Report
Comment
Keros Therapeutics (KROS) Forecast
News
Earnings
Keros Therapeutics (KROS) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Keros Therapeutics (NASDAQ:KROS) Stock
Keros Therapeutics Stock (NASDAQ: KROS)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, December 23, 2024
Truist Securities Maintains Buy on Keros Ther...
Benzinga Newsdesk
Monday, December 16, 2024
Where Keros Therapeutics Stands With Analysts
Benzinga Insights
Oppenheimer Maintains Outperform on Keros The...
Benzinga Newsdesk
Guggenheim Downgrades Keros Therapeutics to N...
Benzinga Newsdesk
Friday, December 13, 2024
Scotiabank Maintains Sector Outperform on Ker...
Benzinga Newsdesk
HC Wainwright & Co. Reiterates Buy on Keros T...
Benzinga Newsdesk
Thursday, December 12, 2024
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights
Dow Tumbles 200 Points; Liquidity Services Shares Spike Higher
Avi Kapoor
William Blair Downgrades Keros Therapeutics t...
Benzinga Newsdesk
TD Cowen Downgrades Keros Therapeutics to Hol...
Benzinga Newsdesk
BTIG Downgrades Keros Therapeutics to Neutral
Benzinga Newsdesk
Gold Falls Sharply; Adobe Shares Dip After Weak Revenue Outlook
Avi Kapoor
Nasdaq Down 50 Points; US Initial Jobless Claims Rise
Avi Kapoor
Keros Therapeutics Loses 75% Value In A Single Session - Here's Why
Vandana Singh
Adobe, Keros Therapeutics, Lovesac And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Avi Kapoor
Keros Therapeutics shares are trading lower a...
Benzinga Newsdesk
Keros Therapeutics Halts Treatment In 3.0 Mg/...
Benzinga Newsdesk
Wednesday, December 11, 2024
Wells Fargo Maintains Overweight on Keros The...
Benzinga Newsdesk
Tuesday, December 10, 2024
Reported Earlier, Keros Therapeutics Highligh...
Benzinga Newsdesk
Friday, December 06, 2024
Keros Therapeutics shares are trading higher....
Benzinga Newsdesk
Thursday, December 05, 2024
Guggenheim Maintains Buy on Keros Therapeutic...
Benzinga Newsdesk
Wednesday, December 04, 2024
Guggenheim Reiterates Buy on Keros Therapeuti...
Benzinga Newsdesk
Tuesday, December 03, 2024
Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst
Vandana Singh
Keros Therapeutics shares are trading higher ...
Benzinga Newsdesk
Takeda Tapped Keros Therapeutics Under A $200...
Benzinga Newsdesk
Friday, November 22, 2024
Keros Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Benzinga Insights
Cantor Fitzgerald Reiterates Overweight on Ke...
Benzinga Newsdesk
Thursday, November 07, 2024
HC Wainwright & Co. Reiterates Buy on Keros T...
Benzinga Newsdesk
Tuesday, November 05, 2024
Keros Therapeutics To Present Three Abstracts...
Benzinga Newsdesk
Thursday, October 24, 2024
Cantor Fitzgerald Reiterates Overweight on Ke...
Benzinga Newsdesk
Wednesday, October 16, 2024
Scotiabank Initiates Coverage On Keros Therap...
Benzinga Newsdesk
Wednesday, September 25, 2024
Kronos Bio To Present Data At ACR Convergence...
Benzinga Newsdesk
Monday, September 23, 2024
Guggenheim Initiates Coverage On Keros Therap...
Benzinga Newsdesk
Thursday, September 12, 2024
B of A Securities Maintains Buy on Keros Ther...
Benzinga Newsdesk
Tuesday, September 03, 2024
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Avi Kapoor
Vaxcyte, Shoals Technologies, Polestar Automotive, Applied Optoelectronics And Other Big Stocks Moving Higher On Tuesday
Avi Kapoor
Keros Therapeutics shares are trading higher ...
Benzinga Newsdesk
Keros Therapeutics Has Closed Screening For T...
Benzinga Newsdesk
Wednesday, August 07, 2024
Keros Therapeutics Q2 EPS $(1.25) Misses $(1....
Benzinga Newsdesk
Tuesday, June 25, 2024
Analyst Sees Keros Therapeutics As Next Acceleron, Set For Major Biotech Growth
Vandana Singh
Oppenheimer Initiates Coverage On Keros Thera...
Benzinga Newsdesk
Tuesday, June 18, 2024
Truist Securities Maintains Buy on Keros Ther...
Benzinga Newsdesk
HC Wainwright & Co. Reiterates Buy on Keros T...
Benzinga Newsdesk
Monday, June 17, 2024
Keros Therapeutics Appointed Jasbir S. Seehra...
Benzinga Newsdesk
Keros Therapeutics Presented Additional Data ...
Benzinga Newsdesk
Thursday, May 09, 2024
HC Wainwright & Co. Reiterates Buy on Keros T...
Benzinga Newsdesk
Wednesday, May 08, 2024
Keros Therapeutics Q1 EPS $(1.21) Beats $(1.3...
Benzinga Newsdesk
Wednesday, March 27, 2024
Piper Sandler Maintains Overweight on Keros T...
Benzinga Newsdesk
Thursday, March 14, 2024
Keros Therapeutics Announces FDA Fast Track D...
Benzinga Newsdesk
Wednesday, March 13, 2024
Truist Securities Reiterates Buy on Keros The...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch